Safety evaluation of pulmonary influenza vaccination in healthy and "asthmatic" mice.
The present study reports animal immuno-toxicological data of pulmonary vaccination against inactivated seasonal influenza. Its aims were (i) to monitor the temporal kinetics of lung inflammation in normal mice over a period of 2 weeks following pulmonary vaccination in order to assess the risk of chronic lung inflammation, (ii) to evaluate the impact of pulmonary vaccination on the asthmatic phenotype in an established allergen-sensitized murine model of asthma. Both sets of experiments were performed using high doses of split influenza virus vaccine. In the first part of this study, we showed that pulmonary influenza vaccination induced a slight local inflammatory response which was limited in duration since it was no longer observed at 2 weeks post-vaccination. At this time point, it has previously been shown that the immunogenic efficacy was maintained. In the second part, we demonstrated that pulmonary influenza vaccination did not significantly exacerbate the cardinal features of asthma, i.e., allergen-specific IgE formation, the development of airway hyperreactivity (AHR) and eosinophilic airway inflammation. Our data therefore suggest that the overall immuno-toxicological profile of pulmonary vaccination against seasonal influenza was acceptable, even in an animal model of pulmonary hypersensitivity.
Minne
Antoine
A
Department of Pharmaceutical Technology, Université catholique de Louvain, Avenue E. Mounier, 73 UCL 73.20, Brussels B-1200, Belgium.
Huaux
François
F
Jaworska
Joanna
J
Rha
Ro-Dug
RD
Hamelmann
Eckard
E
Vanbever
Rita
R
D000280:Administration, Inhalation; D000818:Animals; D001249:Asthma; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry / Q000166:cytology; D005260:Female; D007249:Inflammation; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000009:adverse effects*; D007958:Leukocyte Count; D008168:Lung / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000009:adverse effects
D007252:Influenza Vaccines; D014409:Tumor Necrosis Factor-alpha; D015164:Vaccines, Inactivated